ClinicalTrials.gg
WithdrawnNCT05466747Updated May 6, 2023

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

A Phase 4 interventional study of RYMPHYSIA and Another Available A1PI in Chronic Obstructive Pulmonary Disease (COPD) and Alpha1-Antitrypsin Deficiency, sponsored by Takeda. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the efficacy of RYMPHYSIA [Alpha1-Proteinase Inhibitor (Human)] compared to another available alpha-1 proteinase Inhibitor (A1PI) in adults with A1PI deficiency and COPD-emphysema.

In Part A of the study, participants will be randomly assigned to receive either RYMPHYSIA or another available A1PI for 104 weeks. Participants who were randomized to another available A1PI will enter a 2-week follow-up period after the treatment phase is completed; participants who were randomized to RYMPHYSIA will enter Part B.

In Part B, participants will be randomly assigned to one of two groups and will receive either the same dose of RYMPHYSIA as in Part A or a different dose for an additional 104 weeks, followed by a 2-week follow-up period.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Alpha1-Antitrypsin Deficiency

Keywords

  • TAK-883
  • Chronic Obstructive Pulmonary Disease
  • RYMPHYSIA
03

In context

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult 18 to 75 years at the time of screening.
  • Diagnosis of alpha1-proteinase inhibitor (A1PI) deficiency, defined as follows:

    • Endogenous serum A1PI level lesser than (\<)11 micromolar (μM) or 57.2 micrograms per deciliter (mg/dL) (0.572 gram per liter [g/L]) (as measured at the end of the , if applicable)
    • Genotype ZZ, Z/null, null/null, MMalton/Z, or others that result in A1PI levels \<11 μM. Prior documentation of genotype will be sufficient, or genotyping will be offered at the time of screening
  • Participants eligible for enrollment include newly diagnosed, previously untreated, currently treated, and currently not on treatment but who have received treatment in the past. For those currently on augmentation therapy, a 2-week minimum washout is required until A1PI levels are \<11 μM.
  • Clinically evident (COPD)-emphysema at the time of screening defined by post-bronchodilator of greater than or equal to (≥)30 percent (%) and lesser than or equal to (≤)80% predicted and FEV1/forced vital capacity (FVC) \<70%, corresponding to mild to severe COPD (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] Criteria, stage I-III) (Global Initiative for Chronic Obstructive Lung Disease 2021) and evidence of emphysema on chest imaging (confirmed by the baseline computer topography [CT] densitometry scan).
  • If treated with any respiratory medications including inhaled bronchodilators, inhaled , or systemic corticosteroids (e.g., prednisone ≤10 micrograms per day [mg/day] or its equivalent), the doses of medications should have remained stable for at least 28 days prior to screening.
  • No abnormalities (other than emphysema, bronchitis, or bronchiectasis) detected via chest imaging at the time of screening.
  • Males and non-pregnant, non-lactating females whose screening pregnancy test is negative and willing and able to employ adequate methods.
  • Willing and able to refrain from smoking (including e-cigarettes and vaping of any other substance) for the duration of study.
  • Willing and able to comply with the requirements of the protocol and able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) to participate in the study.

Exclusion criteria

Exclusion:

  • Known ongoing or history of disease other than respiratory or liver disease secondary to A1PI deficiency.
  • If experiencing COVID-19, lower respiratory tract infection (LRTI) and/or acute exacerbation at the time of screening. Participants may be re-screened after clinical resolution of COVID-19, LRTI and/or acute COPD exacerbation and must have also remained stable for at least 6 weeks after the onset of illness.
  • Known ongoing or history of clinically significant cor pulmonale and/or congestive heart failure with (NYHA) Class III/IV symptoms.
  • Has received an organ transplant, has undergone major lung surgery (e.g., lung volume reduction surgery or lobectomy surgery), or is currently on a transplant waiting list.
  • Experiencing an active or has a history of malignancy within 5 years prior to screening, with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment.
  • Current active smoker (including e-cigarettes or vaping, nicotine or any other substance). A participant with a previous history of smoking has to have ceased active smoking at least 6 months prior to screening. Participants with a positive nicotine/cotinine test due to nicotine replacement therapy (eg, patches, chewing gum) or snuff are eligible.
  • Receiving long-term therapy (>28 days) of parenteral or oral corticosteroids at doses greater than 10 mg/day of prednisone or its equivalent.
  • Receiving chronic 24 hours/day oxygen supplementation (other than for an acute COPD exacerbation, or supplemental oxygen with continuous positive airway pressure [CPAP], or bi-level positive airway pressure [BiPAP] for acute respiratory failure).
  • Known selective immunoglobulin A (IgA) deficiency (IgA level \<7 mg/dL at screening) with anti-IgA antibodies and a history of any reaction.
  • Known history of hypersensitivity following infusions of human immunoglobulins, human albumin, blood or blood components.
  • Presence of clinically significant laboratory abnormalities at the screening that in the opinion of the investigator would impact the participant's safety if enrolled in the study.
  • Presence of any of the following that, in the opinion of the investigator, would affect participant's safety or compliance or confound the results of the study, including known clinically significant medical, psychiatric, or cognitive illness, is a recreational drug/alcohol user, or has any other uncontrolled medical condition (e.g., unstable angina, , uncontrolled hypertension).
  • Known exposure to another product/investigational medicinal product (IP/IMP) within 28 days prior to enrollment or is scheduled to participate in another clinical study involving an IP/IMP or investigational device during this study.
  • Participant is a family member or employee of the investigator.
  • If female, participant is pregnant or nursing at the time of enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A: RYMPHYSIA 60 mg/kg

    Participants will receive 60 mg/kg RYMPHYSIA, intravenous (IV) infusion, once every week for up to 104 weeks.

    Biological: RYMPHYSIA

  • Active comparator
    Part A: Another Available A1PI 60 mg/kg

    Participants will receive 60 mg/kg of another available A1PI, IV infusion, once every week for up to 104 weeks.

    Biological: Another Available A1PI

  • Experimental
    Part B: RYMPHYSIA 60 mg/kg

    Participants will receive 60 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.

    Biological: RYMPHYSIA

  • Experimental
    Part B: RYMPHYSIA 120 mg/kg

    Participants will receive 120 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.

    Biological: RYMPHYSIA

Interventions

  • BiologicalRYMPHYSIA

    RYMPHYSIA administered through an IV injection.

    Also known as: Alpha1-PI, TAK-883, A1PI, Alpha1-Proteinase Inhibitor (Human), ARALAST NP

  • Another available A1PI administered through an IV injection.

    Also known as: Alpha1-PI, Alpha1-Proteinase Inhibitor (Human)

06

What researchers measure

Primary outcomes

  1. Part A: Annual Rate of Change in the Physiologically Adjusted Lung Density

    Annual rate of the physiologically adjusted lung density change will be measured as the 15th percentile (PD15) of the lung density measurements as assessed by computed tomography (CT) densitometry at total lung capacity (TLC). CT lung density at the 15th percentile (PD15) is the threshold below which 15 percent (%) of the voxels have lower densities and is used as the parameter for estimating the rate of lung density decline.

    Time frame: Up to Week 104

Secondary outcomes

  1. Part A: Annual Rate of Change in the Plasma Level of Elastin Degradation Products

    The annual rate of change in the plasma levels of elastin degradation products (desmosine and isodesmosine) will be assessed to document the pharmacodynamic (PD) effect of RYMPHYSIA on the activity of neutrophil elastase using high-performance liquid chromatography-mass spectrometry (LC-MS). The assessment of elastin degradation products will be performed for participants in the RYMPHYSIA treatment arm only.

    Time frame: Up to Week 104

  2. Part A: Annual Rate of Change in the Plasma Level of Fibrinogen Degradation Products

    The annual rate of change in the plasma levels of fibrinogen degradation products (Aα-Val360 fragments) will be assessed to document the PD effect of RYMPHYSIA on the activity of neutrophil elastase using high-performance LC-MS. The assessment of fibrinogen degradation products will be performed for participants in the RYMPHYSIA treatment arm only.

    Time frame: Up to Week 104

  3. Part A and Part B: Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

    COPD exacerbations are defined as an acute worsening of respiratory symptoms that results in additional therapy and will be assessed based on the classification in GOLD criteria (2021). The assessment of COPD exacerbations will be performed for participants in the RYMPHYSIA treatment arm only.

    Time frame: Part A, Part B: Up to Week 104

  4. Part A and Part B: Annual Rate of Change in the Post-bronchodilator Forced Expiratory Volume in One Second (FEV1)

    FEV1 is the volume of air that can be forcefully exhaled in the first second after a full inspiration obtained by spirometry. Annual rate of change in the FEV1 will be assessed using spirometry. Spirometric measurements are to be performed in triplicate, and the highest value at each time point is to be used for analyses.

    Time frame: Part A, Part B: Up to Week 104

  5. Part A and Part B: Plasma Trough Level of Antigenic and Functional A1PI for RYMPHYSIA

    Time frame: Part A, Part B: Pre- and post-dose at multiple timepoints (up to 144 hours) up to Week 104

  6. Part A and Part B: Plasma Concentration of Antigenic and Functional A1PI for RYMPHYSIA

    Time frame: Part A, Part B: Pre- and post-dose at multiple timepoints (up to 144 hours) up to Week 104

  7. Part A and Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    The number of participants with TEAEs including drug-related AEs, serious AEs (SAEs), and temporally associated AEs will be assessed.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  8. Part A and Part B: Number of Participants Receiving RYMPHYSIA with Development of Post-treatment Immunogenicity as Measured by Anti-A1PI Binding and Neutralizing Antibodies

    Serum samples will be analyzed for the presence of antibodies against A1PI using a validated anti-A1PI antibody detection (screening and confirmatory) assay at a qualified specialty laboratory. Samples with confirmed positive titers will be further analyzed for the presence of neutralizing antibodies using a validated neutralizing antibody assay at a qualified specialty laboratory.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  9. Part A and Part B: Changes in Laboratory Assessments

    The number of participants who have normal/abnormal values at Baseline compared to normal/abnormal values post-Baseline will be assessed for hematology, clinical chemistry, and urinalysis.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  10. Part A and Part B: Changes in Vital Signs Measurement: Body Temperature

    Percent change from Baseline to post Baseline will be assessed for body temperature.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  11. Part A and Part B: Changes in Vital Signs Measurement: Respiratory Rate

    Percent change from Baseline to post Baseline will be assessed for respiratory rate.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  12. Part A and Part B: Changes in Vital Signs Measurement: Pulse Rate

    Percent change from Baseline to post Baseline will be assessed for pulse rate.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  13. Part A and Part B: Changes in Vital Signs Measurement: Systolic and Diastolic Blood Pressure

    Percent change from Baseline to post Baseline will be assessed for systolic and diastolic blood pressure.

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  14. Part A and Part B: Number of Participants with Changes in Electrocardiogram (ECG) Measurements

    Time frame: Part A, Part B: Up to 2 weeks after the last dose (Up to Week 106)

  15. Part B: Annual Rate of Change in the Physiologically Adjusted Lung Density

    The annual rate of the physiologically adjusted lung density change will be measured as the PD15 of the lung density measurements as assessed by CT densitometry at TLC. CT lung density at the PD15 is the threshold below which 15% of the voxels have lower densities and is used as the parameter for estimating the rate of lung density decline.

    Time frame: Part B: Up to week 104

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Apr 2027, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jul 20, 2022
StartEst.
Jan 1, 2024
Primary completionEst.
Apr 26, 2027
CompletionEst.
May 7, 2029
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05466747
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jan 1, 2024 (estimated)
Primary completion
Apr 26, 2027 (estimated)
Completion
May 7, 2029 (estimated)
Last update
May 6, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion